SLC5A2 and diabetes mellitus: However, whether SGLT2 inhibitor therapy also improves the clinical consequences of diabetes, such as micro- or macrovascular late complications, cannot be answered at present owing to immature clinical data, and provides some uncertainty of this class of drugs.